Praxis Precision surges on positive ulixacaltamide data for essential tremor, but tolerability limits impact. Explore PRAX's ...
Nestle (NSRGY) is downgraded to HOLD with a new price target of 90 CHF, reflecting slimmer upside amid ongoing challenges.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback